CAPR
NASDAQ
US
Capricor Therapeutics, Inc. - Common Stock
$32,11
▲ +$1,99
(+6,61%)
Vol. 1.2M
5
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$1.6B
ROE
-71,0%
Margine
-181,7%
D/E
4,03
Beta
0,74
52W
$4–$40
Consenso Wall Street
16 analisti · Apr 20264
Acquisto forte
11
Compra
1
Mantieni
0
Vendi
0
Vendita forte
93,8%
Rating Compra
Grafico dei Prezzi
Titoli simili
CLDX
Celldex Therapeutics Inc
$1.8B
AGIO
Agios Pharmaceuticals Inc
$1.6B
SLNO
Soleno Therapeutics Inc
$2.5B
STOK
Stoke Therapeutics Inc
P/E 44,2
$1.8B
VRDN
Viridian Therapeutics Inc
$3.0B
SION
Sionna Therapeutics Inc
$1.8B
VCEL
Vericel Corp
P/E 139,2
$1.8B
PVLA
Palvella Therapeutics Inc
$1.2B
ZYME
Zymeworks Inc
$2.0B
Utili
Tasso di battuta: 40,0%
Prossimo report
Mag 11, 2026
Stima EPS: $-0,49
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,49 | — | — |
| Dic 2025 | $-0,55 | $-0,62 | $-0,07 |
| Set 2025 | $-0,56 | $-0,54 | +$0,02 |
| Giu 2025 | $-0,48 | $-0,57 | $-0,09 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | $2.3M | $11.1M | — | — | — | — |
| Utile netto | -$12.6M | -$7.1M | -$24.4M | -$25.9M | -$24.6M | — |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -62.7% | -62.7% | -62.7% | -62.7% | -71.0% | -71.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -181.7% | -181.7% | -181.7% | -181.7% | -181.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 3.22 | 3.22 | 3.22 | 3.22 | 4.03 | 4.03 |
| Current Ratio | 4.37 | 4.37 | 4.37 | 4.37 | 3.59 | 3.59 |
Rapporti chiave
ROA (TTM)
-56,1%
P/S (TTM)
70,50
P/B
4,3
EPS (TTM)
$-1,80
CF/Share
$-1,11
Crescita ricavi 3A
+352,7%
52W High
$40,37
52W Low
$4,30
$4,30
Intervallo 52 settimane
$40,37
Salute finanziaria
Flusso di cassa libero
-$23.7M
Debito netto
-$5.0M
Liquidità
$19.5M
Debito totale
$14.5M
Aggiornato al Set 30, 2025
Як CAPR виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CAPR vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
70,5
▲
449%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
4,3
▲
75%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CAPR vs аналоги Biotechnology
ROE
-71,0%
▼
5%
sotto
peer
(-67,3%)
vs Peer
vs Settore
In linea
Net margin
-181,7%
▲
37%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-56,1%
▼
20%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя CAPR vs аналоги Biotechnology
D/E ratio
4,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
3,6
▼
19%
sotto
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
0,7
▼
24%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CAPR
CAPR
Mediana peer
Industria
CAPR прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CAPR vs аналоги: ключові метрики
Principali azionisti
Top 5: 18,67%Blackrock Inc.
4,96%
$82.4M
Vanguard Group Inc
4,45%
$74.0M
Point72 Asset Management, L…
3,20%
$53.2M
Suvretta Capital Management…
3,10%
$51.6M
Tang Capital Management, LLC
2,96%
$49.1M
Aggiornato al Dic 31, 2025